Clinical trialPhase 2Terminated
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
- Outcome
- Stopped earlyThis investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual. (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 17 June 2024
- Ended
- 9 June 2026
- Enrollment
- 6 participants
- Sites
- 1
- Primary outcomes
- 2-year disease-free survival (2y-DFS)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 11 June 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.